CBP 501

Drug Profile

CBP 501

Alternative Names: CBP-501; Cdc25C phosphatase (211-221)

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator CanBas
  • Class Antineoplastics; Peptides
  • Mechanism of Action 14-3-3 protein inhibitors; Calmodulin antagonists; Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Mesothelioma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 04 Sep 2015 No recent reports on development identified - Phase-II for Mesothelioma (Combination therapy, First-line therapy) in USA, Argentina, Russia (IV)
  • 04 Sep 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in USA, Russia, Canada, Argentina, Brazil, Peru (IV)
  • 12 Aug 2013 CBP 501 is available for licensing in World as of 12 Aug 2013. http://www.canbas.co.jp/eng/About/About-BusinessDevelopment.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top